Generic Drug Approvals

Generic Drug Approvals. First-Time Generic Approvals. Mobic, Propecia, Zithromax

About MOBIC (meloxicam) tablets


November 9th, 2007 by admin


Start

MOBIC is a nonsteroidal anti-inflammatory drug (NSAID) indicated to help relieve the signs and symptoms of osteoarthritis and rheumatoid arthritis. MOBIC is available in 7.5 mg and 15 mg once-daily tablets. Doses higher than 15 mg per day should not be taken due to an increased risk of serious stomach and intestinal problems.

  • You should not take MOBIC if you have had an allergic-type reaction to meloxicam, aspirin or other NSAIDs. MOBIC should not be taken if you have asthma. MOBIC cannot be taken in the place of aspirin and is not intended to help prevent a heart attack or stroke.
  • NSAIDs may increase the chance of a heart attack or stroke, which may occur without warning and could result in death. They should never be taken right before or after heart surgery.
  • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms.
  • NSAIDs may cause serious life-threatening skin reactions. If you develop a rash, discontinue the medication immediately and call your doctor.
  • NSAIDs can cause fluid retention (swelling). Contact your doctor if you experience an unexplained weight gain or any swelling.
  • Pregnant women should consult with their physicians before taking MOBIC. However, MOBIC should not be taken by women in late pregnancy.
  • Tell your doctor if you have advanced kidney disease or any symptoms suggesting liver problems.
  • In clinical trials, the most common side effects were diarrhea, indigestion, headache, and flu-like symptoms. Tell your doctor if you experience any unusual symptoms.

End

Posted in General Information |

Leave a Comment

Please note: Comment moderation is enabled and may delay your comment. There is no need to resubmit your comment.